Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

37.82 -0.47 (-1.23%)
Official Closing Price Updated: 4:10 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales
GSK beat Q1 estimates with $9.46 billion in sales and $1.13 EPS, driven by strong Specialty Medicines and meningitis vaccine performance. 
Via Benzinga
GSK Jumps On Solid Earnings, Says It's 'Well Positioned' To Navigate Tariffs
The company says it's "well positioned" to respond if the Trump administration levies tariffs on pharmaceutical products. 
Via Investor's Business Daily
Topics Economy Government World Trade
Earnings Scheduled For April 30, 2025
Via Benzinga
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years
CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older populations. 
Via Benzinga
UK Becomes First Country To Authorize Blenrep In Two Combo Regimens
GSK's Blenrep approved in the U.K. for multiple myeloma after strong phase 3 data showing improved survival in DREAMM-7 and DREAMM-8 trials. 
Via Benzinga
Peering Into GSK's Recent Short Interest
Via Benzinga
Bear Of The Day: Gsk Plc
GSK PLC is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. 
Via Talk Markets
Topics Stocks / Equities
Earnings Scheduled For February 5, 2025
Via Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
A Look Into GSK Inc's Price Over Earnings
Via Benzinga
New Study Shows Shingles Vaccine Linked To 20% Lower Dementia Risk, GSK Stock Pops
A study of over 280,000 adults found that the shingles vaccine reduced dementia risk by 20%, with a stronger effect in women. 
Via Benzinga
Looking Into GSK's Recent Short Interest
Via Benzinga
FDA Approves GSK's Oral Antibiotic For Urinary Tract Infections For Females Aged 12 Years And Older
The FDA approved GSK's Blujepa for uncomplicated UTIs in female adults and pediatric patients, with phase 3 trials showing strong efficacy vs. nitrofurantoin. 
Via Benzinga
Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion
Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's largest shareholder with over 5%. 
Via Benzinga
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides
HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the... 
Via Benzinga
Topics Government
GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early data on VH184 and VH499 therapies. 
Via Benzinga
Why Moderna Stock Has Surged 20% This Week Despite Mixed News
Recent news has been mixed with a patent win and loss in Germany and the U.S. But Moderna stock has risen markedly this week. 
Via Investor's Business Daily
Topics Intellectual Property
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves. 
Via Benzinga
Topics Earnings
GSK's Once-Daily Inhalers For Smoker's Lung Has Potential Benefits: Independent Organization Report
ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits. 
Via Benzinga
GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review
FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements. 
Via Benzinga
Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial. 
Via Benzinga
Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds
Moderna is under pressure as two of its vaccines hit potential snags. 
Via Investor's Business Daily
Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025
Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half. 
Via Benzinga
FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage recommendations on Feb. 26. 
Via Benzinga
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally. 
Via Benzinga
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty
Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand. 
Via Benzinga
Merck: 4 No-Brainer Reasons to Buy This Dip
Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity. 
Via MarketBeat
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch
A Nevada dairy worker who initially tested positive for bird flu is currently experiencing mild symptoms, including "pink eye." 
Via Benzinga
Electronic Arts Posts Upbeat Earnings, Joins Mattel, Johnson Controls, Mueller Water Products And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion
GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company announced a $2.5 billion share buyback plan. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.